Literature DB >> 1847887

Presence of liver CGRP/amylin receptors in only nonparenchymal cells and absence of direct regulation of rat liver glucose metabolism by CGRP/amylin.

T W Stephens1, W F Heath, R N Hermeling.   

Abstract

Human calcitonin gene-related peptide (hCGRP-1) and human amylin (hA) have been reported to increase hepatic glucose output in vivo and to bind with high affinity to rat liver plasma membranes, resulting in increased cAMP production. These observations have led to the hypothesis that CGRP or amylin may be physiological regulators of liver glucose metabolism. Liver plasma membranes are derived from several cell types, including parenchymal (hepatocyte), Kupffer, endothelial, lipid storage, and smooth muscle cells. Because the parenchymal cell is responsible for the contribution of the liver to whole-body glucose homeostasis, it is important to verify the location and activity of the CGRP/amylin receptor to this cell. These studies separate liver cells prepared by collagenase digestion into parenchymal and nonparenchymal fractions by metrizamide gradient and differential centrifugation. 125I-labeled [Tyr-0]hCGRP-1 bound with high affinity to nonparenchymal cell fraction and was displaced by both hCGRP-1 and hA. hCGRP-1 bound with greater affinity than hA (Kd = 2.1 +/- 1.6 x 10(-11) vs. 2.6 +/- 1.2 x 10(-8) M) in a manner similar to the binding reported for liver plasma membrane fraction. Linear regression of receptor concentration against nonparenchymal cell count per milliliter was significant (r = 0.999, P = 0.026), leading to an estimate of 3000 receptors/cell. The parenchymal cell fraction bound very little 125I-[Tyr-0]hCGRP-1, and regression of receptor concentration against parenchymal cell count per milliliter was not significant (r = -0.708, P = 0.29), suggesting that binding was not due to parenchymal cells but instead to contamination by nonparenchymal cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847887     DOI: 10.2337/diab.40.3.395

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

Review 1.  Islet amyloid polypeptide--a novel controversy in diabetes research.

Authors:  P Westermark; K H Johnson; T D O'Brien; C Betsholtz
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

2.  Role of islet amyloid polypeptide secretion in insulin-resistant humans.

Authors:  A Kautzky-Willer; K Thomaseth; G Pacini; M Clodi; B Ludvik; C Streli; W Waldhäusl; R Prager
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

3.  A mnemonical or negative-co-operativity model for the activation of adenylate cyclase by a common G-protein-coupled calcitonin-gene-related neuropeptide (CGRP)/amylin receptor.

Authors:  M Bushfield; A Savage; N J Morris; M D Houslay
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

4.  Amylin impairment of insulin effects on glycogen synthesis and phosphoenolpyruvate carboxykinase gene expression in rat primary cultured hepatocytes.

Authors:  S Baqué; J J Guinovart; A M Gómez-Foix
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

5.  Effects of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver.

Authors:  M Roden; K Liener; C Fürnsinn; P Nowotny; U Hollenstein; H Vierhapper; W Waldhäusl
Journal:  Diabetologia       Date:  1992-02       Impact factor: 10.122

6.  α-Calcitonin gene-related peptide inhibits autophagy and calpain systems and maintains the stability of neuromuscular junction in denervated muscles.

Authors:  Juliano Machado; Wilian A Silveira; Dawit A Gonçalves; Aline Zanatta Schavinski; Muzamil M Khan; Neusa M Zanon; Mauricio Berriel Diaz; Rüdiger Rudolf; Isis C Kettelhut; Luiz C Navegantes
Journal:  Mol Metab       Date:  2019-07-03       Impact factor: 7.422

7.  Human islet amyloid polypeptide transgenic mice: in vivo and ex vivo models for the role of hIAPP in type 2 diabetes mellitus.

Authors:  J W M Höppener; H M Jacobs; N Wierup; G Sotthewes; M Sprong; P de Vos; R Berger; F Sundler; B Ahrén
Journal:  Exp Diabetes Res       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.